Anti-NMDA Receptor Encephalitis clinical trials at UCSF
1 research study open to eligible people
Anti-NMDA receptor encephalitis is a type of brain illness. At UCSF, we are testing a drug named Satralizumab to see if it can help patients with this condition. We're studying its safety and how it affects the body.
Showing trials for
Pharmacodynamics Of Satralizumab In Patients With Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) Or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis
open to eligible people ages 12 years and up
The purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab in participants with anti-N-methyl-D-aspartic acid receptor (NMDAR) and anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis.
San Francisco, California and other locations
Last updated: